Recent Advances and Emerging Therapies in Atopic Dermatitis

Conclusions

• Pediatric atopic dermatitis care is rapidly expanding beyond topical steroids, with multiple new non-steroidal topical options now approved for younger children and generally showing strong efficacy with acceptable safety.
• The new topical agents appear effective enough to change routine practice, but most evidence still comes from vehicle-controlled trials, so direct comparisons with corticosteroids remain limited.
• Concern about topical steroid withdrawal is widespread but appears to be disproportionate to the number of true pediatric cases, and better diagnostic criteria are still being developed.
• Biologic and JAK therapies are increasingly supported by pediatric data, with dupilumab remaining the broadest option across the youngest ages and newer agents extending treatment choices for older children and adolescents.
• Early advanced systemic treatment may reduce the development of atopic comorbidities such as asthma and allergic rhinitis, and may also improve some non-atopic outcomes like sleep, mood, and developmental concerns.
• Dupilumab may support catch-up growth in some children with atopic dermatitis, suggesting that better disease control can have broader health benefits beyond skin clearance.
• Nemolizumab and lebrikizumab show promising pediatric efficacy signals, but longer-term safety and peer-reviewed data are still needed before their full role is clear.
• Biologic therapy does not have to be lifelong for every patient, and tapering dose frequency after sustained control is a reasonable strategy to test remission.
• Gene-expression profiling may eventually help match patients to the therapy class most likely to work best, especially when deciding between biologics and JAK inhibitors after prior treatment failure.
• JAK inhibitors often produce the fastest and highest response rates, and emerging biomarker work suggests some patients may be particularly good candidates for them.
• Treatment sequencing in pediatric atopic dermatitis is becoming more individualized, often involving switching classes, reducing biologic frequency, or using combination/off-label strategies when response is inadequate or adverse events occur.
• The field is moving toward standardized definitions of low disease activity, control, and remission so that future studies and clinical decisions can be compared more consistently.
• Overall, the presentation argues that pediatric atopic dermatitis management is entering a precision-medicine era in which earlier, more effective therapy may improve skin disease, comorbidities, and quality of life.